The five-year contract with a maximum order limit of $9,509,000 possibly includes production of clinical grade induced pluripotent stem (iPS) cell lines and differentiation of iPS cells in the direction of specific tissue cell type of clinical grade.
Cellectis bioresearch CEO Marc Le Bozec said, "This contract won through a NIH call for tenders is the largest ever secured by Cellectis bioresearch Inc."
Cellectis CEO Andre Choulika said, "This contract award granted by the most prestigious US research organization the NIH is a great recognition of our Science and confirms that Cellectis is one of the major players at developing Stem cell technologies in both in vitro research applications and regenerative medicine."